273 related articles for article (PubMed ID: 30270358)
1. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.
Parker VER; Keppler-Noreuil KM; Faivre L; Luu M; Oden NL; De Silva L; Sapp JC; Andrews K; Bardou M; Chen KY; Darling TN; Gautier E; Goldspiel BR; Hadj-Rabia S; Harris J; Kounidas G; Kumar P; Lindhurst MJ; Loffroy R; Martin L; Phan A; Rother KI; Widemann BC; Wolters PL; Coubes C; Pinson L; Willems M; Vincent-Delorme C; ; Vabres P; Semple RK; Biesecker LG
Genet Med; 2019 May; 21(5):1189-1198. PubMed ID: 30270358
[TBL] [Abstract][Full Text] [Related]
2. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
3. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA-related overgrowth: silver bullets from the cancer arsenal?
Madsen RR; Semple RK
Trends Mol Med; 2022 Apr; 28(4):255-257. PubMed ID: 35272946
[TBL] [Abstract][Full Text] [Related]
5. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
6. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA vascular overgrowth syndromes: an update.
Hughes M; Hao M; Luu M
Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.
Kuentz P; St-Onge J; Duffourd Y; Courcet JB; Carmignac V; Jouan T; Sorlin A; Abasq-Thomas C; Albuisson J; Amiel J; Amram D; Arpin S; Attie-Bitach T; Bahi-Buisson N; Barbarot S; Baujat G; Bessis D; Boccara O; Bonnière M; Boute O; Bursztejn AC; Chiaverini C; Cormier-Daire V; Coubes C; Delobel B; Edery P; Chehadeh SE; Francannet C; Geneviève D; Goldenberg A; Haye D; Isidor B; Jacquemont ML; Khau Van Kien P; Lacombe D; Martin L; Martinovic J; Maruani A; Mathieu-Dramard M; Mazereeuw-Hautier J; Michot C; Mignot C; Miquel J; Morice-Picard F; Petit F; Phan A; Rossi M; Touraine R; Verloes A; Vincent M; Vincent-Delorme C; Whalen S; Willems M; Marle N; Lehalle D; Thevenon J; Thauvin-Robinet C; Hadj-Rabia S; Faivre L; Vabres P; Rivière JB
Genet Med; 2017 Sep; 19(9):989-997. PubMed ID: 28151489
[TBL] [Abstract][Full Text] [Related]
10. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the safety and efficacy of currently used treatment modalities in the treatment of patients with PIK3CA-related overgrowth spectrum.
Bernhard SM; Adam L; Atef H; Häberli D; Bramer WM; Minder B; Döring Y; Laine JE; Muka T; Rössler J; Baumgartner I
J Vasc Surg Venous Lymphat Disord; 2022 Mar; 10(2):527-538.e2. PubMed ID: 34358672
[TBL] [Abstract][Full Text] [Related]
13. Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.
Tian W; Sun L; Zhang Q; Zhao J; Guo Y; Zhong W; Liu L; Meirelles K; Tang S; Zhang J; Huang Y; Yin Y; Zhang N; Zhao Z; Li Q; Wu N; Fang P; Chang F; Wu Z
Mol Genet Genomics; 2022 Mar; 297(2):387-396. PubMed ID: 35122151
[TBL] [Abstract][Full Text] [Related]
14.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
15. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
[TBL] [Abstract][Full Text] [Related]
16. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
Lindhurst MJ; Parker VE; Payne F; Sapp JC; Rudge S; Harris J; Witkowski AM; Zhang Q; Groeneveld MP; Scott CE; Daly A; Huson SM; Tosi LL; Cunningham ML; Darling TN; Geer J; Gucev Z; Sutton VR; Tziotzios C; Dixon AK; Helliwell T; O'Rahilly S; Savage DB; Wakelam MJ; Barroso I; Biesecker LG; Semple RK
Nat Genet; 2012 Jun; 44(8):928-33. PubMed ID: 22729222
[TBL] [Abstract][Full Text] [Related]
17. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients.
Piacitelli AM; Jensen DM; Brandling-Bennett H; Gray MM; Batra M; Gust J; Thaker A; Paschal C; Tsuchiya K; Pritchard CC; Perkins J; Mirzaa GM; Bennett JT
Am J Med Genet A; 2018 Nov; 176(11):2301-2308. PubMed ID: 30063105
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
